New Launch16 Jul 2025, 03:40 pm
Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States
AI Summary
Global pharma major Lupin Limited has announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. This product is bioequivalent to Lotemax® Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc. and is indicated for the treatment of various steroid-responsive inflammatory conditions and post-operative inflammation following ocular surgery. Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax®) had estimated annual sales of USD 55 million in the U.S. (IQVIA MAT May 2025).
Key Highlights
- Lupin launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States
- Bioequivalent to Lotemax® Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc.
- Indicated for the treatment of various steroid-responsive inflammatory conditions
- Used for post-operative inflammation following ocular surgery
- Loteprednol Etabonate Ophthalmic Suspension (RLD Lotemax®) had estimated annual sales of USD 55 million in the U.S. (IQVIA MAT May 2025)